Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MLTA3698A plus a DMARD versus Adalimumab plus a DMARD in active rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)
• MLTA3698A (MLTA3698A)

Snippet

Sponsor: Genentech, Inc. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED